Skip to main content

Advertisement

SpringerLink
Log in

TRIP13 knockdown inhibits the proliferation, migration, invasion, and promotes apoptosis by suppressing PI3K/AKT signaling pathway in U2OS cells

  • Original Article
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Background

Although osteosarcoma (OS) is the most common malignant bone tumor, the biological mechanism underlying its incidence and improvement remains unclear. This study investigated early diagnosis and treatment objectives using bioinformatics strategies and performed experimental verification.

Methods and results

The top 10 OS hub genes—CCNA2, CCNB1, AURKA, TRIP13, RFC4, DLGAP5, NDC80, CDC20, CDK1, and KIF20A—were screened using bioinformatics methods. TRIP13 was chosen for validation after reviewing literature. TRIP13 was shown to be substantially expressed in OS tissues and cells, according to Western blotting (WB) and quantitative real-time polymerase chain reaction data. Subsequently, TRIP13 knockdown enhanced apoptosis and decreased proliferation, migration, and invasion in U2OS cells, as validated by the cell counting kit-8 test, Hoechst 33,258 staining, wound healing assay, and WB. In addition, the levels of p-PI3K/PI3K and p-AKT/AKT in U2OS cells markedly decreased after TRIP13 knockdown. Culturing U2OS cells, in which TRIP13 expression was downregulated, in a medium supplemented with a PI3K/AKT inhibitor further reduced their proliferation, migration, and invasion and increased their apoptosis.

Conclusions

TRIP13 knockdown reduced U2OS cell proliferation, migration, and invasion via a possible mechanism involving the PI3K/AKT signaling pathway.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Code Availability

Not applicable.

References

  1. Carina V, Costa V, Sartori M et al (2019) Adjuvant biophysical therapies in osteosarcoma. Cancers (Basel) 11(3):348

    Article  CAS  Google Scholar 

  2. Harrison DJ, Geller DS, Gill JD et al (2018) Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther 1:39–50

    Article  Google Scholar 

  3. Zhang J, Yan YG, Wang C et al (2015) MicroRNAs in osteosarcoma. Clin Chim Acta 9:17

    Google Scholar 

  4. Luetke A, Meyers PA, Lewis I et al (2014) Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev 4:523–532

    Article  Google Scholar 

  5. Defachelles L, Russo AE, Nelson CR et al (2020) The conserved AAA-ATPase PCH-2 (TRIP13) regulates spindle checkpoint strength. Mol Biol Cell 20:2219–2233

    Article  Google Scholar 

  6. Lu S, Qian J, Guo M et al (2019) Insights into a crucial role of TRIP13 in human cancer. Comput Struct Biotechnol J 17:854–861

    Article  CAS  Google Scholar 

  7. Li ZH, Lei L, Fei LR et al (2021) TRIP13 promotes the proliferation and invasion of lung cancer cells via the Wnt signaling pathway and epithelial-mesenchymal transition. J Mol Histol 1:11–20

    Article  Google Scholar 

  8. Lu S, Guo M, Fan Z et al (2019) Elevated TRIP13 drives cell proliferation and drug resistance in bladder cancer. Am J Transl Res 7:4397–4410

    Google Scholar 

  9. Zhou Y, Zhou B, Pache L et al (2019) Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 1:1523

    Article  Google Scholar 

  10. Pagano A, Breuzard G, Parat F et al (2021) Tau regulates glioblastoma progression, 3D cell organization, growth and migration via the PI3K-AKT axis. Cancers (Basel) 22:5818

    Article  Google Scholar 

  11. Jaffe N (2009) Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res 2009:239–262

    Article  Google Scholar 

  12. Zhang J, Li N, Lu S et al (2021) The role of Notch ligand Jagged1 in osteosarcoma proliferation, metastasis, and recurrence. J Orthop Surg Res 1:226

    Article  Google Scholar 

  13. Chen R, Huang LH, Gao YY et al (2019) Identification of differentially expressed genes in MG63 osteosarcoma cells with drug–resistance by microarray analysis. Mol Med Rep 3:1571–1580

    Google Scholar 

  14. Liu Y, Xi Y, Chen G et al (2020) URG4 mediates cell proliferation and cell cycle in osteosarcoma via GSK3β/β-catenin/cyclin D1 signaling pathway. J Orthop Surg Res 1:226

    Article  Google Scholar 

  15. Watkins TBK, Lim EL, Petkovic M et al (2020) Pervasive chromosomal instability and karyotype order in tumour evolution. Nature 7832:126–132

    Article  Google Scholar 

  16. Ferreira de Oliveira JMP, Almeida JFD, Martins M et al (2021) 3’,4’-Dihydroxyflavonol modulates the cell cycle in cancer cells: implication as a potential combination drug in osteosarcoma. Pharmaceuticals (Basel) 14(7):640

    Article  CAS  Google Scholar 

  17. Gupta D, Silva M, Radziun K et al (2020) Fucoidan inhibition of osteosarcoma cells is species and molecular weight dependent. Mar Drugs 18(2):104

    Article  CAS  Google Scholar 

  18. Zhang G, Zhu Q, Fu G et al (2019) TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c-MYC axis. Br J Cancer 12:1069–1078

    Article  Google Scholar 

  19. Zhou XY, Shu XM (2019) TRIP13 promotes proliferation and invasion of epithelial ovarian cancer cells through Notch signaling pathway. Eur Rev Med Pharmacol Sci 2:522–529

    Google Scholar 

  20. Pastushenko I, Blanpain C (2019) EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol 3:212–226

    Article  Google Scholar 

  21. Saitoh M (2018) Involvement of partial EMT in cancer progression. J Biochem 4:257–264

    Article  Google Scholar 

  22. Dong L, Ding H, Li Y et al (2019) TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer. Int J Biol Macromol 121:200–206

    Article  CAS  Google Scholar 

  23. Xu W, Yang Z, Lu N (2015) A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adh Migr 4:317–324

    Article  Google Scholar 

  24. Yang Q, Jiang W, Hou P (2019) Emerging role of PI3K/AKT in tumor-related epigenetic regulation. Semin Cancer Biol 59:112–124

    Article  CAS  Google Scholar 

  25. Wei R, Xiao Y, Song Y et al (2019) FAT4 regulates the EMT and autophagy in colorectal cancer cells in part via the PI3K-AKT signaling axis. J Exp Clin Cancer Res 1:112

    Article  Google Scholar 

  26. Xu E, Xia X, Jiang C et al (2020) GPER1 silencing suppresses the proliferation, migration, and invasion of gastric cancer cells by inhibiting PI3K/AKT-Mediated EMT. Front Cell Dev Biol 8:591239

    Article  Google Scholar 

  27. Kiaris H, Chatzistamou I, Papavassiliou AG et al (2011) Growth hormone-releasing hormone: not only a neurohormone. Trends Endocrinol Metab 8:311–317

    Article  Google Scholar 

  28. Fanelli M, Tavanti E, Patrizio MP et al (2020) Cisplatin resistance in osteosarcoma: in vitro validation of candidate DNA repair-related therapeutic targets and drugs for tailored treatments. Front Oncol 10:331

    Article  Google Scholar 

  29. Wu X, Yu H, Zhou H et al (2020) Proanthocyanidin B2 inhibits proliferation and induces apoptosis of osteosarcoma cells by suppressing the PI3K/AKT pathway. J Cell Mol Med 20:11960–11971

    Article  Google Scholar 

  30. Aziz MNM, Rahim NFC, Hussin Y et al (2021) Anti-metastatic and anti-angiogenic effects of curcumin analog DK1 on human osteosarcoma cells in vitro. Pharmaceuticals (Basel) 14(6):532

    Article  CAS  Google Scholar 

  31. Zhu MX, Wei CY, Zhang PF et al (2019) Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4. J Exp Clin Cancer Res 1:409

    Article  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

Funding was provided by the Science and Technology Bureau of Lanzhou (Grant No. 2018-3-79).

Author information

Author notes

  1. De-Chen Yu and Xiang-Yi Chen have contributed equally to this work.

Authors and Affiliations

  1. Department of Orthopedics, Lanzhou University Second Hospital, 730000, Lanzhou, China

    De-Chen Yu, Xiang-Yi Chen, Hai-Yu Zhou, Yi-Cun Hu, Rui-Hao Zhang, Xiao-Bo Zhang, Kun Zhang, Mao-Qiang Lin, Xi-Dan Gao & Tao-Wen Guo

  2. Department of Orthopedics, Xigu Branch of the Second Hospital of Lanzhou University, 730000, Lanzhou, China

    De-Chen Yu & Hai-Yu Zhou

  3. Department of Radiotherapy, Air Force Medical University Tangdu Hospital, 710000, Xi’an, China

    De-Quan Yu

  4. Department of cardiology, Air Force Medical University Tangdu Hospital, 710000, Xi’an, China

    Xiao-Lei Yu

Authors
  1. De-Chen Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiang-Yi Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hai-Yu Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. De-Quan Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiao-Lei Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yi-Cun Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rui-Hao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiao-Bo Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mao-Qiang Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Xi-Dan Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Tao-Wen Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Y-DC, C-XY and Z-HY conceived and designed the idea to this paper; L-MQ, G-XD, G-TW, ZK, Z-XB, Z-RH and H-YC participated in its design and coordination and supervised the study. Y-DC, Y-DQ and Y-XL analyzed the data and revised the final paper. All authors read and approved the final version of the manuscript. Y-DC was the first author of this article, Y-DC and C-XY contributed equally to this work.

Corresponding author

Correspondence to Hai-Yu Zhou.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Ethical approval

Our study was approved by the ethics committee of the Second Hospital of Lanzhou University (Project Number: 2021 A-407).

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent for publication

The authors affirm that human research participants provided informed consent for publication of the images in Fig. 4a and c.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yu, DC., Chen, XY., Zhou, HY. et al. TRIP13 knockdown inhibits the proliferation, migration, invasion, and promotes apoptosis by suppressing PI3K/AKT signaling pathway in U2OS cells. Mol Biol Rep 49, 3055–3064 (2022). https://doi.org/10.1007/s11033-022-07133-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-022-07133-6

Keywords

Search

Navigation